Foghorn Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell FHTX and other ETFs, options, and stocks.

About FHTX

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology.

CEO

Adrian Gottschalk

CEOAdrian Gottschalk

Employees

112

Employees112

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2015

Founded2015

Employees

112

Employees112

FHTX Key Statistics

Market cap

285.12M

Market cap285.12M

Price-Earnings ratio

-3.66

Price-Earnings ratio-3.66

Dividend yield

—

Dividend yield—

Average volume

184.84K

Average volume184.84K

High today

$5.19

High today$5.19

Low today

$4.96

Low today$4.96

Open price

$5.02

Open price$5.02

Volume

78.28K

Volume78.28K

52 Week high

$10.25

52 Week high$10.25

52 Week low

$2.94

52 Week low$2.94

Analyst ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own FHTX. This list is generated using Robinhood data, and it’s not a recommendation.

Intellia Therapeutics

Foghorn Therapeutics

Why Robinhood?

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Show more

FHTX Key Statistics

Analyst ratings

100%

People also own

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology.